Oxygen Biotherapeutics jumps on issuance of patent for its treatment of pruritus

Oxygen Biotherapeutics (OXBT +20%) pops after the USPTO issued the drug developer a patent earlier today for its treatment for pruritus - a sensation patients instinctually try to relieve by rubbing or scratching.

The company says it's currently evaluating commercialization strategies, which potentially includes out-licensing for conditions such as allergic contact dermatitis, psoriasis and acne.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs